Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Neuro-Oncology Practice

Clinical experience with tovorafenib in adults with treatment-refractory high and low-grade gliomas

View Full Paper
Ask AI
Bookmark
Share

Authors

MIMaria IoannouSMSetu MehtaADAnirudra Devkota

Discussion

Loading...

Member takes

Overview

Observational analysis reports limited efficacy of tovorafenib in gliomas, suggesting further trials are needed.

Key Points

  • Limited efficacy of tovorafenib was observed in adults with refractory high-grade gliomas.
  • Among seven patients, three demonstrated stable disease for over four months while on therapy.
  • Patients with high-grade gliomas had prior treatments, including BRAF-targeted therapy and radiation.
  • Two patients experienced severe side effects, highlighting potential safety concerns with treatment.

Cite This Study

Ioannou et al. (2025) studied this question.

synapsesocial.com/papers/68c1a41654b1d3bfb60df0abhttps://doi.org/10.1093/nop/npaf068
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma2024 · 23 citations
  2. 2RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults2023 · 528 citations
  3. 3Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors2017 · 178 citations